Recombinant Proteins and Monoclonal Antibodies
- PMID: 29071407
- DOI: 10.1007/10_2017_32
Recombinant Proteins and Monoclonal Antibodies
Abstract
The human genome has become a subject of public interest, whilst the proteome remains the province of specialists. Less appreciated is the human glycoprotein (GP) repertoire (proteoglycome!); however, some 50% of open reading frame genes encode for proteins (P) that may accept the addition of N-linked and/or O-linked sugar chains (oligosaccharides). It is established that the attachment of defined oligosaccharide structures impacts mechanisms of action (MoAs), pharmacokinetics, pharmacodynamics, etc., and is a critical quality attribute (CQA) for recombinant GP therapeutics. The oligosaccharide structure attached at a given site may exhibit structural heterogeneity, and individual structures (glycoforms) may modulate MoAs. The biopharmaceutical industry is challenged, therefore, to produce recombinant GP therapeutics that have structural fidelity to the natural (endogenous) molecule, in non-human cells. Multiple production platforms have been developed that, in addition to the natural glycoform, may produce unnatural glycoforms, including sugar residues that can be immunogenic in human subjects. Following a general introduction to the field, this review discusses glycosylation of recombinant monoclonal antibodies (mAbs), the contribution of glycoforms to MoAs and the development of customised mAb therapeutic glycoforms to optimise MoAs for individual disease indications.
Keywords: Critical quality attributes; Glycoforms; Glycoproteins; IgG subclasses; Mechanisms of action; Oligosaccharides; Recombinant antibody therapeutics.
© 2017. Springer International Publishing AG.
Similar articles
-
Micro-Heterogeneity of Antibody Molecules.Exp Suppl. 2021;112:1-26. doi: 10.1007/978-3-030-76912-3_1. Exp Suppl. 2021. PMID: 34687006 Review.
-
Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.Exp Suppl. 2021;112:481-517. doi: 10.1007/978-3-030-76912-3_15. Exp Suppl. 2021. PMID: 34687020 Review.
-
Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions.Biotechnol Adv. 2018 Sep-Oct;36(5):1505-1523. doi: 10.1016/j.biotechadv.2018.06.008. Epub 2018 Jun 18. Biotechnol Adv. 2018. PMID: 29913209 Review.
-
Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.J Mol Biol. 2003 Jan 31;325(5):979-89. doi: 10.1016/s0022-2836(02)01250-0. J Mol Biol. 2003. PMID: 12527303
-
Glycosylation of recombinant antibody therapeutics.Biotechnol Prog. 2005 Jan-Feb;21(1):11-6. doi: 10.1021/bp040016j. Biotechnol Prog. 2005. PMID: 15903235 Review.
Cited by
-
Glycobiology of rheumatic diseases.Nat Rev Rheumatol. 2023 Jan;19(1):28-43. doi: 10.1038/s41584-022-00867-4. Epub 2022 Nov 23. Nat Rev Rheumatol. 2023. PMID: 36418483 Free PMC article. Review.
-
Cell-free N-glycosylation of peptides using synthetic lipid-linked hybrid and complex N-glycans.Front Mol Biosci. 2023 Sep 12;10:1266431. doi: 10.3389/fmolb.2023.1266431. eCollection 2023. Front Mol Biosci. 2023. PMID: 37767159 Free PMC article.
-
Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation.Front Immunol. 2022 Jan 28;13:818382. doi: 10.3389/fimmu.2022.818382. eCollection 2022. Front Immunol. 2022. PMID: 35154135 Free PMC article.
-
Light Chain Isotype and Antibody-Specificity Impact on Virus Neutralization.Antibodies (Basel). 2025 Jun 17;14(2):50. doi: 10.3390/antib14020050. Antibodies (Basel). 2025. PMID: 40558104 Free PMC article.
-
The Role of Clinical Glyco(proteo)mics in Precision Medicine.Mol Cell Proteomics. 2023 Jun;22(6):100565. doi: 10.1016/j.mcpro.2023.100565. Epub 2023 May 9. Mol Cell Proteomics. 2023. PMID: 37169080 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources